Highlights from the 16th Annual Psychopharmacology Update Gail Erlick Robinson, M.D., D.Psych. and Thomas Roth, Ph.D. Compare and contrast risks associated with continuing or discontinuing psychopharmacologic agents during pregnancy. Prevent relapse of depression in pregnant women. Counsel women on safe breastfeeding while taking psychopharmacologic agents. Recognize complications and comorbidities associated with insomnia. Evaluate the effects of treatment of insomnia on various health and quality of life issues.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Bad for the Bones: Prescription Medications and Skeletal Deterioration Jonathan Graf, M.D. Recognize patients at increased risk for glucocorticoid-induced osteoporosis (GIO). Discuss the role of bisphosphonates in the prevention of GIO. Reduce risk for osteoporosis in men with low bone mineral density (BMD) on androgen deprivation therapy. Review data about effects of bisphosphonates in women with breast cancer who are treated with aromatase inhibitors. Describe effects of thiazolidinediones on BMD and fracture risk in patients with diabetes.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Pharmacotherapy? Where do we Stand? Ruth Lynfield, M.D. and Krissa Klotzle, Pharm.D., B.C.P.S. Summarize the history, current features, and magnitude of the problem of antibiotic resistance and elaborate on the relationship between agricultural use of antibiotics and human health. Implement antibiotic stewardship measures within institutions and individual practices. Prescribe new anticoagulants, antiplatelet medications, and antiviral agents against hepatitis C virus appropriately. Incorporate postmarketing data on the safety of citalopram and simvastatin into therapeutic decisions for these agents. Assess the likelihood that patients may not be adhering to their medication regimens.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Treatment of Psychosis, Part 2: Antipshychotic Medications Stephen R. Marder, M.D. and John W. Goethe, M.D. Initiate appropriate trials of APs to maximize response in patients with psychosis. Compare and contrast efficacy and side effects associated with first- and second-generation APs. Reduce negative symptoms of schizophrenia through the use of psychosocial therapies. Avoid extrapyramidal symptoms and tardive dyskinesia in patients on APs. Identify trends in approved and unapproved uses of APs in patients <18 yr of age.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Pharmacologic Therapy for Depression and Anxiety Philip G. Janicak, M.D. Recognize common causes of treatment failure in patients with depression and anxiety. Prevent misdiagnosis in patients with depressive symptoms. Conduct adequate trials of pharmacologic treatments for patients with anxiety and depression. Treat patients with obsessive-compulsive disorder. Target less well-known neurotransmitter systems implicated in depression.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Additional Continuing Education Options Available...
If you have taken the current Clinical Pharmacology course listed above or if you are seeking additional continuing education credits, please visit: Medical Courses Coming Soon, for an abbreviated outline of additional medical courses available.
ASI Now Offers 9 NEW Specialties! Click the links below for the current course outline and full information!
Here is what our clients are saying about ASI's CME seminars...
"..great change away from seminar schedules and limits of location! Info sheets were very clear.Process is painless. Service Prompt." Larry,MD,Austin, TX
"This has been a great find for me! Learning, fullfilling my CME needs and traveling is a great combination!" Arnold,MD,Alexandria,VA
" I completed Clinical Pharmacology in Las Vegas, on a flexible schedule..a perfect conference!" Shania, NP, Honalulu, Hawaii
Back to Top of Clinical Pharmacology CME Review Page
